These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 31223080)

  • 1. Clinical Usefulness of N-terminal Prohormone of Brain Natriuretic Peptide and High Sensitivity Troponin T in Patients with Heart Failure Undergoing Cardiac Resynchronization Therapy.
    Debska-Kozlowska A; Ksiazczyk M; Warchol I; Lubinski A
    Curr Pharm Des; 2019; 25(14):1671-1678. PubMed ID: 31223080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of NT-pro BNP monitoring to identify echocardiographic responders following cardiac resynchronization therapy.
    Magne J; Dubois M; Champagne J; Dumesnil JG; Pibarot P; Philippon F; O'Hara G; Sénéchal M
    Cardiovasc Ultrasound; 2009 Aug; 7():39. PubMed ID: 19695099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mid-regional pro-atrial natriuretic peptide to predict clinical course in heart failure patients undergoing cardiac resynchronization therapy.
    Arrigo M; Truong QA; Szymonifka J; Rivas-Lasarte M; Tolppanen H; Sadoune M; Gayat E; Cohen-Solal A; Ruschitzka F; Januzzi JL; Singh JP; Mebazaa A
    Europace; 2017 Nov; 19(11):1848-1854. PubMed ID: 28096288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decrease of plasma N-terminal pro beta-type natriuretic peptide as a predictor of clinical improvement after cardiac resynchronization therapy for heart failure.
    Ding LG; Hua W; Zhang S; Chu JM; Chen KP; Wang Y; Wang FZ; Chen X
    Chin Med J (Engl); 2009 Mar; 122(6):617-21. PubMed ID: 19323922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of preimplantation B-type natriuretic peptide level for predicting response to cardiac resynchronization therapy.
    Lellouche N; De Diego C; Cesario DA; Vaseghi M; Horowitz BN; Mahajan A; Wiener I; Boyle NG; Fonarow GC; Shivkumar K
    Am J Cardiol; 2007 Jan; 99(2):242-6. PubMed ID: 17223426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony.
    Fruhwald FM; Fahrleitner-Pammer A; Berger R; Leyva F; Freemantle N; Erdmann E; Gras D; Kappenberger L; Tavazzi L; Daubert JC; Cleland JG
    Eur Heart J; 2007 Jul; 28(13):1592-7. PubMed ID: 17298973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the effects of cardiac resynchronization therapy on pathophysiological pathways of heart failure using surrogate biomarkers.
    Sunman H; Özkan A; Yorgun H; Canpolat U; Karabulut E; Bayrak T; Kaya EB; Tokgözoğlu L; Özer N; Özkara A; Aytemir K; Oto A
    Cardiol J; 2018; 25(1):42-51. PubMed ID: 28980281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantification of ventricular resynchronization reserve by radionuclide phase analysis in heart failure patients: a prospective long-term study.
    Dauphin R; Nonin E; Bontemps L; Vincent M; Pinel A; Bonijoly S; Barborier D; Ribier A; Fernandes CM; Bert-Marcaz P; Itti R; Chevalier P
    Circ Cardiovasc Imaging; 2011 Mar; 4(2):114-21. PubMed ID: 21239562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain natriuretic peptide and the risk of ventricular tachyarrhythmias in mildly symptomatic heart failure patients enrolled in MADIT-CRT.
    Medina A; Moss AJ; McNitt S; Zareba W; Wang PJ; Goldenberg I
    Heart Rhythm; 2016 Apr; 13(4):852-9. PubMed ID: 26724489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain natriuretic peptide and cardiac resynchronization therapy in patients with mildly symptomatic heart failure.
    Brenyo A; Barsheshet A; Rao M; Huang DT; Zareba W; McNitt S; Hall WJ; Peterson DR; Solomon SD; Moss AJ; Goldenberg I
    Circ Heart Fail; 2013 Sep; 6(5):998-1004. PubMed ID: 23801020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of brain natriuretic peptide level at implant in predicting mortality in patients with advanced but stable heart failure receiving cardiac resynchronization therapy.
    El-Saed A; Voigt A; Shalaby A
    Clin Cardiol; 2009 Nov; 32(11):E33-8. PubMed ID: 19816874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coronary sinus biomarker sampling compared to peripheral venous blood for predicting outcomes in patients with severe heart failure undergoing cardiac resynchronization therapy: the BIOCRT study.
    Truong QA; Januzzi JL; Szymonifka J; Thai WE; Wai B; Lavender Z; Sharma U; Sandoval RM; Grunau ZS; Basnet S; Babatunde A; Ajijola OA; Min JK; Singh JP
    Heart Rhythm; 2014 Dec; 11(12):2167-75. PubMed ID: 25014756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of collagen turnover biomarkers in cardiac resynchronization therapy: A subanalysis of the TRUST CRT randomized trial population.
    Sokal A; Lenarczyk R; Kowalski O; Mitrega K; Pluta S; Stabryla-Deska J; Streb W; Urbanik Z; Krzeminski TF; Kalarus Z
    Heart Rhythm; 2016 May; 13(5):1088-1095. PubMed ID: 26776557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-Terminal Pro B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T Levels Are Related to the Extent of Hibernating Myocardium in Patients With Ischemic Heart Failure.
    Zelt JGE; Liu PP; Erthal F; deKemp RA; Wells G; O'Meara E; Garrard L; Beanlands RSB; Mielniczuk LM
    Can J Cardiol; 2017 Nov; 33(11):1478-1488. PubMed ID: 28966019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Body composition in heart failure and the impact of cardiac resynchronisation therapy: a proof-of-concept study.
    McAloon CJ; Hyndman S; Ansell V; O'Hare P; Randeva H; Osman F
    Open Heart; 2020; 7(1):e001105. PubMed ID: 32153788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationships between cardiac resynchronization therapy and N-terminal pro-brain natriuretic peptide in patients with heart failure and markers of cardiac dyssynchrony: an analysis from the Cardiac Resynchronization in Heart Failure (CARE-HF) study.
    Berger R; Shankar A; Fruhwald F; Fahrleitner-Pammer A; Freemantle N; Tavazzi L; Cleland JG; Pacher R
    Eur Heart J; 2009 Sep; 30(17):2109-16. PubMed ID: 19493864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of cardiac resynchronization therapy on inflammatory biomarkers and cardiac remodeling: The paradox of functional and echocardiographic response.
    Almeida-Morais L; Abreu A; Oliveira M; Silva Cunha P; Rodrigues I; Portugal G; Rio P; Soares R; Mota Carmo M; Cruz Ferreira R
    Rev Port Cardiol (Engl Ed); 2018 Feb; 37(2):105-113. PubMed ID: 29503051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new biomarker of cardiac resynchronization therapy response: cGMP to mature BNP ratio.
    Yokoyama Y; Kataoka N; Nakai M; Matsuo A; Fujiwara A; Wakamiya A; Ueda N; Nakajima K; Kamakura T; Wada M; Yamagata K; Ishibashi K; Inoue Y; Miyamoto K; Nagase S; Noda T; Aiba T; Takahama H; Izumi C; Kinugawa K; Minamino N; Kusano K
    J Cardiol; 2022 Jun; 79(6):727-733. PubMed ID: 35016810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of N-terminal pro-B-type natriuretic peptide increase with exercise for predicting cardiovascular mortality in patients with heart failure.
    Koç M; Bozkurt A; Acartürk E; Sahin DY; Unal I
    Am J Cardiol; 2008 Apr; 101(8):1157-62. PubMed ID: 18394451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of serum NT-ProBNP predicts improvement in cardiac function and favorable prognosis after cardiac resynchronization therapy for heart failure.
    Yu CM; Fung JW; Zhang Q; Chan CK; Chan I; Chan YS; Kong SL; Sanderson JE; Lam CW
    J Card Fail; 2005 Jun; 11(5 Suppl):S42-6. PubMed ID: 15948100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.